Nordøy T, Kolstad A, Tuck M K, Aaberge I S, Husebekk A, Kaminski M S
Department of Oncology, University Hospital of Tromsø, Tromsø, N-9038, Norway.
Clin Immunol. 2001 Jul;100(1):40-8. doi: 10.1006/clim.2001.5050.
Thirty-one previously untreated patients with follicular low-grade B-cell non-Hodgkin's lymphoma expressing the CD20 antigen were treated with iodine-131 tositumomab therapy between 1996 and 1998. The therapy led to a temporary depletion of peripheral blood B-lymphocytes. Recovery of B-cells occurred in most cases by 3 to 6 months and in all patients by 12 months posttherapy. A temporary decline in T-cell subpopulations, but no reduction in serum immunoglobulin levels, could be observed. ELISA techniques were used to detect specific antibodies against rubella, mumps, varicella zoster, measles, and tetanus. Almost all patients remained seropositive against the different antigens during the 1- to 2-year follow-up. No significant reduction in antibody concentrations to tetanus or measles could be detected. The data show that acquired humoral immunity against common antigens appears to be preserved despite a temporary loss of B-lymphocytes.
1996年至1998年间，31例先前未经治疗、表达CD20抗原的滤泡性低度B细胞非霍奇金淋巴瘤患者接受了碘-131托西莫单抗治疗。该治疗导致外周血B淋巴细胞暂时耗竭。大多数病例在治疗后3至6个月B细胞恢复，所有患者在治疗后12个月B细胞恢复。可观察到T细胞亚群暂时下降，但血清免疫球蛋白水平无降低。采用ELISA技术检测风疹、腮腺炎、水痘带状疱疹、麻疹和破伤风特异性抗体。在1至2年的随访中，几乎所有患者对不同抗原仍保持血清学阳性。未检测到破伤风或麻疹抗体浓度有显著降低。数据表明，尽管B淋巴细胞暂时缺失，但针对常见抗原的获得性体液免疫似乎得以保留。
